PT - JOURNAL ARTICLE ED - , TI - Can â–¼verteporfin help in macular degeneration? AID - 10.1136/dtb.2001.39430 DP - 2001 Apr 01 TA - Drug and Therapeutics Bulletin PG - 30--32 VI - 39 IP - 4 4099 - http://dtb.bmj.com/content/39/4/30.short 4100 - http://dtb.bmj.com/content/39/4/30.full SO - Drug Ther Bull2001 Apr 01; 39 AB - Relevant BNF section: 11.8.2Age-related macular degeneration (AMD), a disorder affecting older people, is the commonest cause of severe visual impairment in the UK.1 It involves degeneration of the central retina (the macula) that results in diminished capacity for detailed visual tasks, such as reading, writing and recognising faces. For most people with AMD there is no effective treatment. &#9660Verteporfin* (Visudyne - Novartis Ophthalmics) was licensed last year for use in conjunction with laser activation (photodynamic therapy) for the treatment of "age-related macular degeneration in patients with predominantly classic subfoveal neovascularisation".3 Here, we review the place of this treatment.